Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Financing Activities (2021 - 2025)

Aligos Therapeutics' Cash from Financing Activities history spans 5 years, with the latest figure at $123000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 26.8% year-over-year to $123000.0; the TTM value through Dec 2025 reached $101.6 million, up 28529.58%, while the annual FY2025 figure was $101.6 million, 28529.58% up from the prior year.
  • Cash from Financing Activities reached $123000.0 in Q4 2025 per ALGS's latest filing, up from -$53000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $101.7 million in Q1 2025 to a low of -$177000.0 in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $13.5 million, with a median of $89000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: tumbled 1800.0% in 2024, then skyrocketed 535584.21% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $552000.0 in 2021, then plummeted by 78.08% to $121000.0 in 2022, then surged by 72574.38% to $87.9 million in 2023, then tumbled by 99.89% to $97000.0 in 2024, then increased by 26.8% to $123000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Cash from Financing Activities are $123000.0 (Q4 2025), -$53000.0 (Q3 2025), and -$177000.0 (Q2 2025).